Arbutus Biopharma Corporation
ABUS
$3.59
$0.010.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 110.29% | -95.71% | 36.44% | 0.40% | -10.75% |
| Total Depreciation and Amortization | -96.67% | -0.90% | -0.89% | -5.62% | 0.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -100.78% | 162.00% | 84.70% | -47.47% | 100.92% |
| Change in Net Operating Assets | -446.18% | 2,400.87% | 90.84% | -190.61% | 196.47% |
| Cash from Operations | -17.61% | -29.82% | 50.26% | -42.97% | 24.83% |
| Capital Expenditure | -- | -- | -- | 100.00% | 98.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.47% | -15.91% | 212.61% | -221.93% | -16.62% |
| Cash from Investing | 37.55% | -15.38% | 211.89% | -221.95% | -15.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -83.73% | 95.92% | -19.94% | -92.72% | -0.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -83.73% | 95.92% | -19.94% | -92.72% | -0.25% |
| Foreign Exchange rate Adjustments | 425.00% | 112.12% | -760.00% | 162.50% | 38.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -54.96% | -83.36% | 114.49% | -257.17% | 17.07% |